用植物化学物质针对类风湿性关节炎的危险因素:一种抗炎症的视角
1Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Sector-125, Noida, UP, 201313, India.
Inflammopharmacology
|July 1, 2025
概括
本综述探讨了炎症体如何导致关节炎,并强调了药用植物和植物化学品作为关节疾病更安全,更有效的抗炎治疗的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症是关键的免疫反应,疾病被分类为急性或慢性关节疾病.
- 风湿性关节炎 (RA) 是炎症性,而骨关节炎 (OA) 涉及炎症性细胞因子和偶发性炎症.
- 传统的关节炎治疗方法在有效性和副作用方面存在局限性.
研究的目的:
- 审查生物因素和炎症酶在关节炎病原发生中的作用.
- 整合有关具有抗关节炎功能的药用植物和植物化学品的信息.
- 探索关节炎管理的补充和替代治疗策略.
主要方法:
- 在体外,体内,临床前和临床研究的文献综述.
- 对激活炎症酶的生物触发物的分析.
- 对传统医学和植物化学品对抗炎作用的评估.
主要成果:
- 生物因素激活炎症酶,在关节炎中启动炎症级联.
- 药用植物和植物化学物质显示出显著的抗炎性质.
- 这些天然化合物为关节炎治疗提供了潜力,副作用较少.
结论:
- 关节炎的管理需要超越传统药物的多维策略.
- 来自药用植物的植物药物疗法为关节炎治疗提供了一个有前途的途径.
- 对天然化合物的进一步研究可以导致更安全,更有效的抗关节炎药物.
相关概念视频
Genome-wide Association Studies-GWAS
14.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
14.4K
The JAK-STAT Signaling Pathway
9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.3K
T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
239
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
239
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
277
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
277
Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204


